Company intelligence / Profile preview

21 Legends

Somerset, New Jersey, United States21legendsbv.com ↗

Ownership: Private
Employees: ~1200
Development stage: Other

Overview

Legend Biotech is a global leader in cell therapies, with its lead product CARVYKTI® approved and commercially available for relapsed/refractory multiple myeloma. The company reported groundbreaking five-year survival data at ASCO 2025 and continues to expand its pipeline through partnerships and internal R&D. It has a strategic partnership with Johnson & Johnson for the commercialization of CARVYKTI®, as well as a licensing agreement with Novartis for DLL3-targeted therapies.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyGamma-delta T cell therapyNatural killer (NK) cell-based immunotherapyAllogeneic chimeric antigen receptor T-cell therapyAutologous chimeric antigen receptor T-cell therapy
Industry: Biotech

Partnerships

Johnson & Johnson/Janssen – co-development/commercialization of CARVYKTI®Novartis – license agreement on DLL3-targeted therapies

Beyond the preview

Go deeper on 21 Legends.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 21 Legends.

Explore the full profile